BR9707947A - Derivado de ácido hidroxâmico para uso com o tratamento de doneças relacionadas a degradaç o de tecido conectivo - Google Patents
Derivado de ácido hidroxâmico para uso com o tratamento de doneças relacionadas a degradaç o de tecido conectivoInfo
- Publication number
- BR9707947A BR9707947A BR9707947A BR9707947A BR9707947A BR 9707947 A BR9707947 A BR 9707947A BR 9707947 A BR9707947 A BR 9707947A BR 9707947 A BR9707947 A BR 9707947A BR 9707947 A BR9707947 A BR 9707947A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- connective tissue
- hydroxamic acid
- ulceration
- tissue degradation
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 210000002808 connective tissue Anatomy 0.000 title abstract 2
- 230000008354 tissue degradation Effects 0.000 title abstract 2
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000036269 ulceration Effects 0.000 abstract 2
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 108060005980 Collagenase Proteins 0.000 abstract 1
- 102000029816 Collagenase Human genes 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 229960002424 collagenase Drugs 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 108091007196 stromelysin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1309896P | 1996-03-08 | 1996-03-08 | |
| PCT/US1997/002568 WO1997032846A1 (en) | 1996-03-08 | 1997-03-03 | Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9707947A true BR9707947A (pt) | 1999-07-27 |
Family
ID=21758301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9707947A BR9707947A (pt) | 1996-03-08 | 1997-03-03 | Derivado de ácido hidroxâmico para uso com o tratamento de doneças relacionadas a degradaç o de tecido conectivo |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5712300A (enExample) |
| EP (1) | EP0898562B1 (enExample) |
| JP (1) | JP2000506163A (enExample) |
| KR (1) | KR19990087597A (enExample) |
| CN (1) | CN1210517A (enExample) |
| AT (1) | ATE231490T1 (enExample) |
| AU (1) | AU707180B2 (enExample) |
| BR (1) | BR9707947A (enExample) |
| DE (1) | DE69718634T2 (enExample) |
| DK (1) | DK0898562T3 (enExample) |
| ES (1) | ES2191823T3 (enExample) |
| ID (1) | ID16144A (enExample) |
| MY (1) | MY117762A (enExample) |
| NO (1) | NO312956B1 (enExample) |
| NZ (1) | NZ330922A (enExample) |
| PE (1) | PE55698A1 (enExample) |
| PL (1) | PL328693A1 (enExample) |
| PT (1) | PT898562E (enExample) |
| RU (1) | RU2168497C2 (enExample) |
| TW (1) | TW448172B (enExample) |
| UA (1) | UA61906C2 (enExample) |
| WO (1) | WO1997032846A1 (enExample) |
| ZA (1) | ZA971902B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932579A (en) * | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
| WO1997048688A1 (en) * | 1996-06-21 | 1997-12-24 | Pharmacia & Upjohn Company | Thiadiazole amide mmp inhibitors |
| ATE289590T1 (de) * | 1996-09-27 | 2005-03-15 | Upjohn Co | Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren |
| GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| US6566373B2 (en) | 1997-05-06 | 2003-05-20 | Smithkline Beecham Corporation | Protease inhibitors |
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| US5883131A (en) * | 1997-07-09 | 1999-03-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| WO1999006340A2 (en) | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE69915004T2 (de) * | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| SK12452001A3 (sk) | 1999-03-03 | 2002-04-04 | The Procter & Gamble Company | Zlúčenina vytvárajúca inhibítor metaloproteinázy, farmaceutický prostriedok, spôsob prípravy liečiva a liečivo |
| WO2000051993A2 (en) | 1999-03-03 | 2000-09-08 | The Procter & Gamble Company | Dihetero-substituted metalloprotease inhibitors |
| EP1165546A2 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| AU2002230385A1 (en) * | 2000-09-25 | 2002-04-15 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| EP1355901A2 (en) | 2001-01-11 | 2003-10-29 | Bristol-Myers Squibb Pharma Company | 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) |
| CA2434044A1 (en) | 2001-01-11 | 2002-07-18 | Bristol-Myers Squibb Pharma Company | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| DE60207384T2 (de) * | 2001-03-01 | 2006-08-03 | Smithkline Beecham Corp. | Peptid-deformylase-hemmer |
| JP4314340B2 (ja) * | 2001-06-15 | 2009-08-12 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | ピロリジン二環性化合物 |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| TWI294778B (en) * | 2002-03-13 | 2008-03-21 | Smithkline Beecham Corp | Peptide deformylase inhibitors |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| PL374117A1 (en) * | 2002-05-29 | 2005-10-03 | Merck & Co, Inc. | Compounds useful in the treatment of anthrax and inhibiting lethal factor |
| US20050176686A1 (en) * | 2002-07-23 | 2005-08-11 | 4Sc Ag | Novel compounds as histone deacetylase inhibitors |
| EP1626961B1 (en) * | 2003-05-17 | 2011-11-02 | Korea Research Institute of Bioscience and Biotechnology | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| US7122560B2 (en) | 2003-06-18 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| EP1663201A4 (en) * | 2003-07-15 | 2009-10-28 | Korea Res Inst Of Bioscience | USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| KR101070036B1 (ko) * | 2003-07-23 | 2011-10-04 | 노르딕 바이오사이언스 에이/에스 | 골관절염에 대한 칼시토닌의 용도 |
| CN1950354A (zh) * | 2004-05-11 | 2007-04-18 | 默克公司 | N－磺酰化－氨基酸衍生物的制备方法 |
| US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| JP2008528624A (ja) * | 2005-01-28 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | フェニル置換ピロリドン |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US9738604B2 (en) | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
| US20140081017A1 (en) * | 2012-09-14 | 2014-03-20 | Methylgene Inc. | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents |
| WO2015024011A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| AU2014306451B2 (en) | 2013-08-16 | 2019-01-17 | Duke University | Substituted hydroxamic acid compounds |
| US9908851B2 (en) | 2013-08-16 | 2018-03-06 | Duke University | 2-piperidinyl substituted N,3-dihydroxybutanamides |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1360583A (en) * | 1918-02-18 | 1920-11-30 | Great Lakes Dredge And Dock Co | Car-dumper |
| EP0042100A1 (de) * | 1980-06-13 | 1981-12-23 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel |
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
| US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| ATE195117T1 (de) * | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| EP0712390B1 (en) * | 1993-08-02 | 1998-12-09 | Celltech Therapeutics Limited | Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors |
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
-
1997
- 1997-02-21 TW TW086102076A patent/TW448172B/zh not_active IP Right Cessation
- 1997-03-03 EP EP97908674A patent/EP0898562B1/en not_active Expired - Lifetime
- 1997-03-03 NZ NZ330922A patent/NZ330922A/xx unknown
- 1997-03-03 DK DK97908674T patent/DK0898562T3/da active
- 1997-03-03 ES ES97908674T patent/ES2191823T3/es not_active Expired - Lifetime
- 1997-03-03 BR BR9707947A patent/BR9707947A/pt active Search and Examination
- 1997-03-03 AT AT97908674T patent/ATE231490T1/de not_active IP Right Cessation
- 1997-03-03 UA UA98105283A patent/UA61906C2/uk unknown
- 1997-03-03 DE DE69718634T patent/DE69718634T2/de not_active Expired - Fee Related
- 1997-03-03 PT PT97908674T patent/PT898562E/pt unknown
- 1997-03-03 CN CN97192171A patent/CN1210517A/zh active Pending
- 1997-03-03 RU RU98118372/04A patent/RU2168497C2/ru not_active IP Right Cessation
- 1997-03-03 AU AU20525/97A patent/AU707180B2/en not_active Ceased
- 1997-03-03 JP JP9531784A patent/JP2000506163A/ja not_active Withdrawn
- 1997-03-03 PL PL97328693A patent/PL328693A1/xx unknown
- 1997-03-03 KR KR1019980707039A patent/KR19990087597A/ko not_active Abandoned
- 1997-03-03 WO PCT/US1997/002568 patent/WO1997032846A1/en not_active Ceased
- 1997-03-04 PE PE1997000155A patent/PE55698A1/es not_active Application Discontinuation
- 1997-03-04 US US08/811,821 patent/US5712300A/en not_active Expired - Fee Related
- 1997-03-05 ZA ZA971902A patent/ZA971902B/xx unknown
- 1997-03-06 ID IDP970713A patent/ID16144A/id unknown
- 1997-03-07 MY MYPI97000965A patent/MY117762A/en unknown
-
1998
- 1998-09-07 NO NO19984112A patent/NO312956B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO984112L (no) | 1998-11-06 |
| KR19990087597A (ko) | 1999-12-27 |
| TW448172B (en) | 2001-08-01 |
| PE55698A1 (es) | 1998-09-16 |
| DK0898562T3 (da) | 2003-05-12 |
| MY117762A (en) | 2004-08-30 |
| WO1997032846A1 (en) | 1997-09-12 |
| DE69718634D1 (de) | 2003-02-27 |
| ES2191823T3 (es) | 2003-09-16 |
| ZA971902B (en) | 1998-09-07 |
| UA61906C2 (en) | 2003-12-15 |
| JP2000506163A (ja) | 2000-05-23 |
| ATE231490T1 (de) | 2003-02-15 |
| CN1210517A (zh) | 1999-03-10 |
| NO312956B1 (no) | 2002-07-22 |
| ID16144A (id) | 1997-09-04 |
| DE69718634T2 (de) | 2003-10-30 |
| NO984112D0 (no) | 1998-09-07 |
| EP0898562A1 (en) | 1999-03-03 |
| AU2052597A (en) | 1997-09-22 |
| EP0898562B1 (en) | 2003-01-22 |
| RU2168497C2 (ru) | 2001-06-10 |
| PL328693A1 (en) | 1999-02-15 |
| AU707180B2 (en) | 1999-07-01 |
| US5712300A (en) | 1998-01-27 |
| PT898562E (pt) | 2003-06-30 |
| NZ330922A (en) | 2000-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9707947A (pt) | Derivado de ácido hidroxâmico para uso com o tratamento de doneças relacionadas a degradaç o de tecido conectivo | |
| DK0900211T3 (da) | Thiadiazolyl(thio)urinstoffer, der er nyttige som matrixmetalloproteaseinhibitorer | |
| CO4970765A1 (es) | Composiciones de bajo ph que contienen acido para el cuidado personal que exhiben picazon reducida | |
| DK165003C (da) | Chlorsulfat | |
| ES2055409T3 (es) | Inhibidores de colagenasa basados en el acido hidroxamico. | |
| DK0568306T3 (da) | Anitkonvulsive fructopyranose cycliske sulfitter og sulfater | |
| NO950849L (no) | Derivater av valproin og 2-valproensyreamider og anvendelse som antikonvulsanter | |
| DK1134215T3 (da) | 2-oxo-imidazolidin-4-carboxylsyrehydroxaminforbindelser, som inhiberer matrixmetalloproteinaser | |
| DE69719385D1 (de) | Mmp-hemmende thiadiazolylamide | |
| HUT39966A (en) | Insecticides containing as active substance acetilized sacharin-derivatives and process for production of this active substance | |
| AU6602594A (en) | New phosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them | |
| CA2244903A1 (en) | Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation | |
| FI963168A0 (fi) | Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia | |
| FR2775976B1 (fr) | Composition pharmaceutique ou cosmetique contenant un precurseur d'actif hydrolysable par la glucocerebrosidase | |
| ECSP972048A (es) | Nuevos derivados del acido hidroxamico utiles para el tratamiento de enfermedades relacionados con la degradacion del tejido conectivo | |
| TH33716A (th) | อนุพันธ์ไฮดรอกแซมิกแอซิดชนิดใหม่ที่ใช้ประโยชน์สำหรับรักษาโรคที่เกี่ยวข้องกับการสลายตัวของเนื้อเยื่อยึดต่อ | |
| IT1250655B (it) | Derivato dell'acido 4-clorofenossiacetico ad attivita' antiossidante eantiinvecchiamento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |